UY33539A - Compuestos químicos alk - Google Patents

Compuestos químicos alk

Info

Publication number
UY33539A
UY33539A UY0001033539A UY33539A UY33539A UY 33539 A UY33539 A UY 33539A UY 0001033539 A UY0001033539 A UY 0001033539A UY 33539 A UY33539 A UY 33539A UY 33539 A UY33539 A UY 33539A
Authority
UY
Uruguay
Prior art keywords
alk
chemical compounds
formula
methods
compounds
Prior art date
Application number
UY0001033539A
Other languages
English (en)
Inventor
Aquila Brian
Kamhi Victor
Peng Bo
Pontz Timothy
Jamal Carlos Saeh
Thakur Kumar
Yang Bin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY33539A publication Critical patent/UY33539A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide

Abstract

La presente invención se refiere a compuestos de Fórmula (I) y/o Fórmula (Ia) y a sus sales, composiciones farmacéuticas, métodos de empleo y métodos para su preparación. Estos compuestos inhiben la actividad cinasa de ALK y, por lo tanto, se pueden utilizar para tratar el cáncer.
UY0001033539A 2010-08-02 2011-08-01 Compuestos químicos alk UY33539A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36991710P 2010-08-02 2010-08-02
US37205510P 2010-08-09 2010-08-09
US39094410P 2010-10-07 2010-10-07

Publications (1)

Publication Number Publication Date
UY33539A true UY33539A (es) 2012-02-29

Family

ID=45527326

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033539A UY33539A (es) 2010-08-02 2011-08-01 Compuestos químicos alk

Country Status (14)

Country Link
US (1) US8461170B2 (es)
EP (1) EP2601186A2 (es)
JP (1) JP2013534221A (es)
KR (1) KR20130096241A (es)
CN (1) CN103153982A (es)
AR (1) AR089550A1 (es)
AU (1) AU2011287386A1 (es)
BR (1) BR112013002587A2 (es)
CA (1) CA2805827A1 (es)
MX (1) MX2013001361A (es)
RU (1) RU2013109132A (es)
TW (1) TW201219383A (es)
UY (1) UY33539A (es)
WO (1) WO2012017239A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122014026114B1 (pt) 2011-07-27 2021-01-12 Astrazeneca Ab compostos de fórmula (i), composição farmacêutica e uso do composto
CN102899882B (zh) * 2012-11-07 2014-08-06 西南大学 超亲水涤纶织物的磷酸制备方法
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN105085550B (zh) * 2014-05-21 2017-05-24 海门慧聚药业有限公司 一类alk激酶抑制剂及其制备方法
CN106559991B (zh) * 2014-06-19 2019-09-20 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
JP6606278B2 (ja) * 2015-08-31 2019-11-13 ウーシー ショアンリャン バイオテクノロジー カンパニー，リミティド ２−アリールアミノピリジン、ピリミジン又はトリアジン誘導体及びその製造方法と使用
CN106810553B (zh) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
KR20220130249A (ko) 2016-05-26 2022-09-26 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
CN110214138A (zh) * 2017-01-26 2019-09-06 韩美药品株式会社 嘧啶化合物及其药物用途
JP7005742B2 (ja) * 2017-07-26 2022-01-24 鼎科医療技術（蘇州）有限公司 表面液化薬物コートバルーン
EP3778590A4 (en) * 2018-04-09 2021-12-22 ShanghaiTech University COMPOUND TARGETING PROTEIN DEGRADATION, ANTITUMOR USE, INTERMEDIATE AND USE OF THE INTERMEDIATE
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
CN116763792B (zh) * 2023-06-19 2024-03-12 西安国际医学中心医院 Hg-14-10-04在制备治疗食管鳞癌的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
EP1991545A2 (en) 2005-12-23 2008-11-19 AstraZeneca AB Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
CA2659582A1 (en) * 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2008150799A1 (en) * 2007-06-01 2008-12-11 Smithkline Beecham Corporation Imidazopyridine kinase inhibitors
US20110118238A1 (en) 2007-08-23 2011-05-19 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2010049731A1 (en) * 2008-10-29 2010-05-06 Astrazeneca Ab Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors

Also Published As

Publication number Publication date
BR112013002587A2 (pt) 2019-09-24
JP2013534221A (ja) 2013-09-02
AU2011287386A1 (en) 2013-03-07
WO2012017239A2 (en) 2012-02-09
TW201219383A (en) 2012-05-16
AR089550A1 (es) 2014-09-03
KR20130096241A (ko) 2013-08-29
WO2012017239A3 (en) 2012-04-05
RU2013109132A (ru) 2014-09-10
CA2805827A1 (en) 2012-02-09
MX2013001361A (es) 2013-05-17
CN103153982A (zh) 2013-06-12
EP2601186A2 (en) 2013-06-12
US20120028924A1 (en) 2012-02-02
US8461170B2 (en) 2013-06-11

Similar Documents

Publication Publication Date Title
UY33539A (es) Compuestos químicos alk
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
NI201500167A (es) Compuestos químicos
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
BR112014030743A2 (pt) inibidores de neprilisina
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
CR20150371A (es) Inhibidores de prmt5 y sus usos
PH12015500689B1 (en) Azaquinazoline inhibitors of atypical protein kinase c
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112015003859A8 (pt) Compostos de pirazolopirimidina como inibidores de quinase
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
UY33587A (es) Nuevos compuestos como inhibidores de quinasas syk y jak
BR112013016595A2 (pt) inibidores de neprilisina
NI201500096A (es) Compuesto químicos
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
BR112012024586A2 (pt) compostos de purina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200813